NCT06484790View on ClinicalTrials.gov

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

PHASE1RecruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

April 7, 2026

Study Completion Date

April 7, 2027

Conditions

Tumor, Solid

Interventions

DRUG

NW-301V

TCR-T T cell targeting KRAS G12V mutation

DRUG

NW-301D

TCR-T T cell targeting KRAS G12D mutation

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Sponsors

Collaborators (1)

Neowise Biotechnology

All Listed Sponsors

collaborator

Neowise Biotechnology

INDUSTRY

lead

Ting Deng

OTHER